Navigation Links
New Drug ALT-711 decreases blood vessel stiffness

A novel drug that breaks down collagen bonds in the body's blood vessels significantly decreases the stiffness of vessels in older people, according to a study conducted by National Institute on Aging (NIA) scientists and others. The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain complications of diabetes. The drug, ALT-711, snips bonds or crosslinks created in the arteries and other tissues when glucose attaches to the protein collagen. //

Crosslinks are cable-like structures that inhibit the natural flexibility of collagen strands. They tend to proliferate with age. Crosslinks appear to toughen tissues and may contribute to some of the deterioration associated with aging and diabetes, such as elevated systolic blood pressure, stiff arteries, and impaired kidney function.

The ability to reduce vascular stiffness could have a major influence on reducing deaths from heart disease. For the current study, investigators at nine U.S. clinical centers recruited 93 people over the age of 50 who showed evidence of vascular stiffening, including high systolic blood pressure and pulse pressure of at least 60 mm Hg.

The participants were randomly divided into two groups-those who received daily doses of ALT-711 and those who were given a placebo daily. After 56 days, arterial pulse pressure - the difference between systolic and diastolic blood pressures - was significantly reduced among those taking the drug compared to the placebo group.


'"/>




Page: 1

Related medicine news :

1. Headache decreases appetite
2. Contraceptives decreases Libido
3. Alcohol decreases risk of dementia
4. Cooling decreases heart attack effects
5. Vitamin E decreases high blood pressure in kidney failure
6. Light therapy decreases depression during pregnancy
7. Perceived stress decreases vaccine response
8. Infant receives first bloodless liver transplant
9. Spouses and other partners lower blood pressure says new research
10. H2O - a cure for low blood pressure
11. Uncontrolled blood pressure
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... ... August 18, 2017 , ... ... at creating a transparent, verifiable database to help the cannabis industry move towards ... Paragon hopes to deliver a faster technology with lower fees. Paragon will build ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has ... These illustrations show the diversity of the breastfeeding mothers, using bright colors ... of sizes. These illustrations are also available on tote bags, notepads, smartphone cases, ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! ... children to both their parents and God. “Congratulations! It's A Boy! God’s Gift: A ... a couple from Long Island, New York. , Published by Christian Faith Publishing, Dale ...
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/2/2017)... Calif. , Aug. 2, 2017 ... Continental Who,s Who as a Pinnacle Lifetime Professional ... the Key Account Manager at Turing Pharmaceuticals, AG. ... negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience as ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: